Evidence map›Paper›PMID 27479614›Full record

ArticleAnnals of internal medicine2016

Trends in Prevalence of Chronic Kidney Disease in the United States.

Daniel Murphy, Charles E McCulloch, Feng Lin, Tanushree Banerjee, Jennifer L Bragg-Gresham, Mark S Eberhardt, Hal Morgenstern, Meda E Pavkov, Rajiv Saran, Neil R Powe and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05997641 (A Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered DF-003 Following Single), which is not on this map. Cited by 323 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
323citing papers in PubMed, 4 pooled it
37.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05997641 phase1active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered DF-003 Following Single (Part 1) and Multiple (Part 2) Ascending Doses in Healthy Subjects

TypeinterventionalSponsorShanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)Ran2023 to 2026Enrolled96ConditionsHealthy, Safety and TolerabilityArmsDF-003, Placebo
3 · Its place in the literature

Who cites it

323 citing papers in PubMed, 4 syntheses or guidelines pooled it, 606 citations in OpenAlex.

  1. Pooled it
  2. Characteristics and quality of clinical practice guidelines for diabetic kidney disease: a systematic review.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Sex differences in renal acid-base regulation.Current opinion in nephrology and hypertension · 2026
    Review
  11. Article
  12. Article
  13. Body roundness index and mortality risk in patients with chronic kidney disease: moving beyond the obesity paradox.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Observational
  14. Review
  15. Review
  16. Article
  17. National Prevalence, Regional Distribution, and Risk Factors for CKD in Taiwan.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  18. Article
  19. Article
  20. Article

263 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Daniel MurphyFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Charles E McCullochFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Feng LinFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Tanushree BanerjeeFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Jennifer L Bragg-GreshamFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Mark S EberhardtFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Hal MorgensternFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Meda E PavkovFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Rajiv SaranFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Neil R PoweFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Chi-Yuan HsuFrom the University of Minnesota, Minneapolis, Minnesota; University of California, San Francisco, San Francisco, California; University of Michigan, Ann Arbor, Michigan; National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland; and Centers for Disease Control and Prevention, Atlanta, Georgia.
Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team
Centers for Disease Control and Prevention · USUniversity of California, San Francisco · USUniversity of Michigan–Ann Arbor · USUniversity of Minnesota · US

Funding

ESTABLISHING A SURVEILLANCE SYSTEM FOR CHRONIC KIDNEY DISEASE IN THE U.S.U58DP003839 · DP · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POWE, NEIL R. · 2011 to 2014
$1.8M
Patient Oriented Research in Kidney DiseaseK24DK092291 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 2011 to 2020
$1.2M
NCCDPHP CDC HHS U58 DP003839NIDDK NIH HHS K24 DK092291
6 · The paper itself

Abstract

Background: Trends in the prevalence of chronic kidney disease (CKD) are important for health care policy and planning. Objective: To update trends in CKD prevalence. Design: Repeated cross-sectional study. Setting: NHANES (National Health and Nutrition Examination Survey) for 1988 to 1994 and every 2 years from 1999 to 2012. Participants: Adults aged 20 years or older. Measurements: Chronic kidney disease (stages 3 and 4) was defined as an estimated glomerular filtration rate (eGFR) of 15 to 59 mL/min/1.73 m2, estimated with the Chronic Kidney Disease Epidemiology Collaboration equation from calibrated serum creatinine measurements. An expanded definition of CKD also included persons with an eGFR of at least 60 mL/min/1.73 m2 and a 1-time urine albumin-creatinine ratio of at least 30 mg/g. Results: The unadjusted prevalence of stage 3 and 4 CKD increased from the late 1990s to the early 2000s. Since 2003 to 2004, however, the overall prevalence has largely stabilized (for example, 6.9% prevalence in 2003 to 2004 and in 2011 to 2012). There was little difference in adjusted prevalence of stage 3 and 4 CKD overall in 2003 to 2004 versus 2011 to 2012 after age, sex, race/ethnicity, and diabetes mellitus status were controlled for (P = 0.26). Lack of increase in CKD prevalence since the early 2000s was observed in most subgroups and with an expanded definition of CKD that included persons with higher eGFRs and albuminuria. Limitation: Serum creatinine and albuminuria were measured only once in each person. Conclusion: In a reversal of prior trends, there has been no appreciable increase in the prevalence of stage 3 and 4 CKD in the U.S. population overall during the most recent decade. Primary Funding Source: American Society of Nephrology Foundation for Kidney Research Student Scholar Grant Program, Centers for Disease Control and Prevention, and National Institutes of Health.

Indexed as

AdultAgedAged, 80 and overAlbuminuriaCreatinineCross-Sectional StudiesFemaleGlomerular Filtration RateHumansMaleMiddle AgedNutrition SurveysPrevalenceRenal Insufficiency, ChronicTime FactorsUnited StatesCreatinine

Identifiers

PMID27479614
PMCPMC5552458
OpenAlexW2495583055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.